case_images: PMC4043808_01
case_images: Multiphase computed tomography before sorafenib treatment.. Notes: (A) An 8 cm heterogeneous enhancement liver tumor at segment 8 in arterial phase (arrow); (B) right portal vein thrombosis in portal phase (arrow).
case_images: ott-7-829Fig1.jpg
case_images: PMC4043808_01_ott-7-829Fig1.jpg
case_images: f1-ott-7-829
case_images: Multiphase liver computed tomography (CT) showed an 8 cm liver tumor with early enhance, early wash out, and right PVT at segment 8 of the right lobe (Figure 1).
case_images: Poorly differentiated hepatocellular carcinoma with trabecular pattern (hematoxylin and eosin, x200).
case_images: ott-7-829Fig2.jpg
case_images: PMC4043808_01_ott-7-829Fig2.jpg
case_images: f2-ott-7-829
case_images: Liver tumor biopsy confirmed the diagnosis of poorly differentiated HCC with a trabecular pattern (Figure 2).
case_images: Serial changes of observable parameters in this patient with an effective treatment of sorafenib: AFP level, tumor size, arterial enhancement of tumor, and PVT. Notes: (A) Shows serial changes of observable parameters in this patient with an effective treatment of sorafenib: AFP level, tumor size, arterial enhancement of tumor and PVT. The AFP level declined rapidly over time, followed by absence of tumor arterial enhancement, decrease tumor size, and PVT regression; (B) images 1-6 shows serial changes of liver tumor in CT before treatment (8cm, arrow), on day 42 (3.7cm), day 65 (2.9cm), month 6 (2.8cm) and the end of follow-up at month 19 (2.3cm); (C) shows serial changes of right PVT regression, and gradual shrinkage to the right anterior portal branch from images 1 to 6 (arrow). + no significant change of right PVT, - right PVT regression, localized to right anterior branch.. Abbreviations: AFP, alpha-fetoprotein; PVT, portal vein thrombosis; QOD, every other day; CT, computed tomography.
case_images: ott-7-829Fig3.jpg
case_images: PMC4043808_01_ott-7-829Fig3.jpg
case_images: f3-ott-7-829
case_images: Sorafenib therapy was started at the standard dose of 800 mg/day on June 8, 2012 (Figure 3). Figure 3 shows the serial changes of observable parameters in this patient with sorafenib treatment.